Literature DB >> 2893534

Effects of celiprolol on the bronchial reactivity in asthma.

C Bruschi1, L Casali, I Cerveri, V Peona, M C Zoia.   

Abstract

In 10 patients with bronchial asthma but normal ventilatory function, celiprolol, a cardioselective beta-adrenoreceptor antagonist, did not significantly affect forced expiratory volume in 1 second (FEV1) or airways resistance (Raw). In contrast, metoprolol substantially reduced FEV1 and increased Raw. In addition, compared with metoprolol, celiprolol induced a greater recovery of FEV1 and Raw after methacholine-induced bronchoconstriction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2893534     DOI: 10.1016/0002-9149(88)90487-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Required beta blocker profile in the elderly.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

Review 2.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 3.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

4.  Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease.

Authors:  R Fogari; A Zoppi; F Tettamanti; L Poletti; G Rizzardi; G Fiocchi
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

5.  Celiprolol: A Unique Selective Adrenoceptor Modulator.

Authors:  James J Nawarskas; Angela Cheng-Lai; William H Frishman
Journal:  Cardiol Rev       Date:  2017 Sep/Oct       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.